Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2025-10-01 00:00:00 ET · period of report 2025-09-29 · accession 0001882764-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-01 | 2025-09-29 | ELVN | Hohl Benjamin | CFO | S - Sale+OE | $20.40 | -3,250 | 23.0K | -12% | -$66.3K |
| D | 2025-10-01 | 2025-09-29 | ELVN | Hohl Benjamin | CFO | M - OptEx | $2.48 | +3,250 | 26.2K | +14% | +$8,060 |
| D | 2025-10-01 | 2025-09-29 | ELVN | Hohl Benjamin | CFO | M - OptEx | $0.00 | -3,250 | 105.1K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-29 | S | D | 3,250 | $20.40 | 23,000 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $20.025 to $20.71. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 2 | Common | Common Stock | 2025-09-29 | M | A | 3,250 | $2.48 | 26,250 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2025-09-29 | M | D | 3,250 | $0.00 | 105,056 | D | $2.48 · — to 2031-08-02 | 3,250 Common Stock | (F3) All of the shares subject to this option are fully vested and exercisable as of the date hereof. |